The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies
Oncotarget. 2023 Dec 20;14:997-1008. doi: 10.18632/oncotarget.28543.ABSTRACTTo evade cell cycle controls, malignant cells rely upon rapid expression of select proteins to mitigate proapoptotic signals resulting from damage caused by both cancer treatments and unchecked over-proliferation. Cyclin-dependent kinase 9 (CDK9)-dependent signaling induces transcription of downstream oncogenes promoting tumor growth, especially in hyperproliferative 'oncogene-addicted' cancers, such as human hematological malignancies (HHMs). GFH009, a potent, highly selective CDK9 small molecule inhibitor, demonstrated antiproliferative activity ...
Source: Oncotarget - December 20, 2023 Category: Cancer & Oncology Authors: Fusheng Zhou Lili Tang Siyuan Le Mei Ge Dragan Cicic Fubo Xie Jinmin Ren Jiong Lan Qiang Lu Source Type: research

Therapeutically harnessing cancer stem cell-derived exosomes
Oncotarget. 2023 Dec 20;14:995-996. doi: 10.18632/oncotarget.28542.NO ABSTRACTPMID:38117541 | PMC:PMC10732254 | DOI:10.18632/oncotarget.28542 (Source: Oncotarget)
Source: Oncotarget - December 20, 2023 Category: Cancer & Oncology Authors: Yong Teng Source Type: research

The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies
Oncotarget. 2023 Dec 20;14:997-1008. doi: 10.18632/oncotarget.28543.ABSTRACTTo evade cell cycle controls, malignant cells rely upon rapid expression of select proteins to mitigate proapoptotic signals resulting from damage caused by both cancer treatments and unchecked over-proliferation. Cyclin-dependent kinase 9 (CDK9)-dependent signaling induces transcription of downstream oncogenes promoting tumor growth, especially in hyperproliferative 'oncogene-addicted' cancers, such as human hematological malignancies (HHMs). GFH009, a potent, highly selective CDK9 small molecule inhibitor, demonstrated antiproliferative activity ...
Source: Oncotarget - December 20, 2023 Category: Cancer & Oncology Authors: Fusheng Zhou Lili Tang Siyuan Le Mei Ge Dragan Cicic Fubo Xie Jinmin Ren Jiong Lan Qiang Lu Source Type: research

Therapeutically harnessing cancer stem cell-derived exosomes
Oncotarget. 2023 Dec 20;14:995-996. doi: 10.18632/oncotarget.28542.NO ABSTRACTPMID:38117541 | PMC:PMC10732254 | DOI:10.18632/oncotarget.28542 (Source: Oncotarget)
Source: Oncotarget - December 20, 2023 Category: Cancer & Oncology Authors: Yong Teng Source Type: research

The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies
Oncotarget. 2023 Dec 20;14:997-1008. doi: 10.18632/oncotarget.28543.ABSTRACTTo evade cell cycle controls, malignant cells rely upon rapid expression of select proteins to mitigate proapoptotic signals resulting from damage caused by both cancer treatments and unchecked over-proliferation. Cyclin-dependent kinase 9 (CDK9)-dependent signaling induces transcription of downstream oncogenes promoting tumor growth, especially in hyperproliferative 'oncogene-addicted' cancers, such as human hematological malignancies (HHMs). GFH009, a potent, highly selective CDK9 small molecule inhibitor, demonstrated antiproliferative activity ...
Source: Oncotarget - December 20, 2023 Category: Cancer & Oncology Authors: Fusheng Zhou Lili Tang Siyuan Le Mei Ge Dragan Cicic Fubo Xie Jinmin Ren Jiong Lan Qiang Lu Source Type: research

Therapeutically harnessing cancer stem cell-derived exosomes
Oncotarget. 2023 Dec 20;14:995-996. doi: 10.18632/oncotarget.28542.NO ABSTRACTPMID:38117541 | PMC:PMC10732254 | DOI:10.18632/oncotarget.28542 (Source: Oncotarget)
Source: Oncotarget - December 20, 2023 Category: Cancer & Oncology Authors: Yong Teng Source Type: research

The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies
Oncotarget. 2023 Dec 20;14:997-1008. doi: 10.18632/oncotarget.28543.ABSTRACTTo evade cell cycle controls, malignant cells rely upon rapid expression of select proteins to mitigate proapoptotic signals resulting from damage caused by both cancer treatments and unchecked over-proliferation. Cyclin-dependent kinase 9 (CDK9)-dependent signaling induces transcription of downstream oncogenes promoting tumor growth, especially in hyperproliferative 'oncogene-addicted' cancers, such as human hematological malignancies (HHMs). GFH009, a potent, highly selective CDK9 small molecule inhibitor, demonstrated antiproliferative activity ...
Source: Oncotarget - December 20, 2023 Category: Cancer & Oncology Authors: Fusheng Zhou Lili Tang Siyuan Le Mei Ge Dragan Cicic Fubo Xie Jinmin Ren Jiong Lan Qiang Lu Source Type: research

Therapeutically harnessing cancer stem cell-derived exosomes
Oncotarget. 2023 Dec 20;14:995-996. doi: 10.18632/oncotarget.28542.NO ABSTRACTPMID:38117541 | PMC:PMC10732254 | DOI:10.18632/oncotarget.28542 (Source: Oncotarget)
Source: Oncotarget - December 20, 2023 Category: Cancer & Oncology Authors: Yong Teng Source Type: research

Addendum: Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study
Oncotarget. 2023 Dec 12;14:971. doi: 10.18632/oncotarget.28491.NO ABSTRACTPMID:38085073 | PMC:PMC10715040 | DOI:10.18632/oncotarget.28491 (Source: Oncotarget)
Source: Oncotarget - December 12, 2023 Category: Cancer & Oncology Authors: Ellery Altshuler Raymond Richhart William King Mahmoud Aryan Akash Mathavan Akshay Mathavan Keegan Hones Daniel F Leach Logan Pucci Joshua Riklan Pat Haley Ilyas Sahin Brian Ramnaraign Sherise Rogers Ibrahim Nassour Steven Hughes Thomas J George Jesus Fab Source Type: research

Correction: Abnormal topological organization in white matter structural networks in survivors of acute lymphoblastic leukaemia with chemotherapy treatment
Oncotarget. 2023 Dec 12;14:970. doi: 10.18632/oncotarget.28535.NO ABSTRACTPMID:38085097 | PMC:PMC10715039 | DOI:10.18632/oncotarget.28535 (Source: Oncotarget)
Source: Oncotarget - December 12, 2023 Category: Cancer & Oncology Authors: Liwei Zou Lianzi Su Rongmiao Qi Fang Bao Xianjing Fang Longsheng Wang Zhimin Zhai Dan Li Suisheng Zheng Source Type: research

Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability
Oncotarget. 2023 Dec 12;14:977-994. doi: 10.18632/oncotarget.28541.ABSTRACTClassic Hodgkin lymphoma (CHL), which accounts for 90-95% of all cases of Hodgkin lymphoma, is the most frequent cancer in adolescents and the most frequent lymphoma in adolescents and young adults. Despite progressive improvements over past decades and the general sensitivity of CHL to frontline chemotherapy, approximately 10-15% of patients have refractory disease that either does not respond to such therapy or progresses after an initial partial response. In patients with refractory or relapsed disease, standard treatment until recently consisted...
Source: Oncotarget - December 12, 2023 Category: Cancer & Oncology Authors: Fl ávia Dias Xavier Danielle Le ão Cordeiro de Farias Abrah ão Elias Hallack Neto Glaciano Nogueira Ribeiro Marco Aurelio Salvino de Araujo Thiago Xavier Carneiro Otavio Cesar Carvalho Guimar ães Baiocchi Source Type: research

Melatonin and carcinogenesis in mice: the 50th anniversary of relationships
Oncotarget. 2023 Dec 12;14:972-976. doi: 10.18632/oncotarget.28537.ABSTRACTThe history of studies of melatonin effects on cancer in mice is outlined, the main lesson being that the systemic in vivo effects of melatonin on animals may overwhelm the in vitro effects found using tissue explants or cell cultures. In particular, the timing of melatonin administration is of crucial importance for using the drug, which is freely available over counter and thus needs no licensing for its applications in oncology.PMID:38085132 | PMC:PMC10715041 | DOI:10.18632/oncotarget.28537 (Source: Oncotarget)
Source: Oncotarget - December 12, 2023 Category: Cancer & Oncology Authors: Vladimir N Anisimov Alexey G Golubev Source Type: research

Addendum: Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study
Oncotarget. 2023 Dec 12;14:971. doi: 10.18632/oncotarget.28491.NO ABSTRACTPMID:38085073 | PMC:PMC10715040 | DOI:10.18632/oncotarget.28491 (Source: Oncotarget)
Source: Oncotarget - December 12, 2023 Category: Cancer & Oncology Authors: Ellery Altshuler Raymond Richhart William King Mahmoud Aryan Akash Mathavan Akshay Mathavan Keegan Hones Daniel F Leach Logan Pucci Joshua Riklan Pat Haley Ilyas Sahin Brian Ramnaraign Sherise Rogers Ibrahim Nassour Steven Hughes Thomas J George Jesus Fab Source Type: research

Correction: Abnormal topological organization in white matter structural networks in survivors of acute lymphoblastic leukaemia with chemotherapy treatment
Oncotarget. 2023 Dec 12;14:970. doi: 10.18632/oncotarget.28535.NO ABSTRACTPMID:38085097 | PMC:PMC10715039 | DOI:10.18632/oncotarget.28535 (Source: Oncotarget)
Source: Oncotarget - December 12, 2023 Category: Cancer & Oncology Authors: Liwei Zou Lianzi Su Rongmiao Qi Fang Bao Xianjing Fang Longsheng Wang Zhimin Zhai Dan Li Suisheng Zheng Source Type: research

Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability
Oncotarget. 2023 Dec 12;14:977-994. doi: 10.18632/oncotarget.28541.ABSTRACTClassic Hodgkin lymphoma (CHL), which accounts for 90-95% of all cases of Hodgkin lymphoma, is the most frequent cancer in adolescents and the most frequent lymphoma in adolescents and young adults. Despite progressive improvements over past decades and the general sensitivity of CHL to frontline chemotherapy, approximately 10-15% of patients have refractory disease that either does not respond to such therapy or progresses after an initial partial response. In patients with refractory or relapsed disease, standard treatment until recently consisted...
Source: Oncotarget - December 12, 2023 Category: Cancer & Oncology Authors: Fl ávia Dias Xavier Danielle Le ão Cordeiro de Farias Abrah ão Elias Hallack Neto Glaciano Nogueira Ribeiro Marco Aurelio Salvino de Araujo Thiago Xavier Carneiro Otavio Cesar Carvalho Guimar ães Baiocchi Source Type: research